|
|
|
|
| LEADER |
00000cam a2200000 7i4500 |
| 001 |
0000091780 |
| 005 |
20200521093000.0 |
| 008 |
170530s2016 nju eng |
| 020 |
|
|
|a 9781119053323
|
| 020 |
|
|
|a 9781119053330
|
| 040 |
|
|
|a UniSZA
|e rda
|
| 050 |
0 |
0 |
|a RA1238
|b .D78 2016
|
| 060 |
1 |
0 |
|a QV 600
|b .D794 2016
|
| 090 |
0 |
0 |
|a RA1238
|b .D78 2016
|
| 245 |
0 |
0 |
|a Drug discovery toxicology :
|b from target assessment to translational biomarkers
|c edited by Yvonne Will, J. Eric Mcduffie, Andrew J. Olaharski, Brandon D. Jeffy
|
| 264 |
|
1 |
|a Hoboken, New Jersey :
|b John Wiley & Sons
|c c2016
|
| 300 |
|
|
|a xxvi, 556 pages :
|b illustration ;
|c 29 cm.
|
| 336 |
|
|
|a text
|2 rdacontent
|
| 337 |
|
|
|a unmediated
|2 rdamedia
|
| 338 |
|
|
|a volume
|2 rdacarrier
|
| 504 |
|
|
|a Includes bibliographical references and index
|
| 505 |
0 |
|
|a 1. Safety lead optimization strategies -- 2. Basis for in vitro-in PK translation -- 3. Predicting organ toxicity -- 4. Addressing the false negative space-increasing predictivity -- 5. Stem cells in toxicology -- 5. Current status of preclinical in vivo toxicity biomarkers -- 6. Kidney injury biomarkers -- 7. Best practices in biomarker evaluations
|
| 650 |
|
0 |
|a Drug Discovery
|
| 650 |
|
0 |
|a Drugs
|x Testing
|
| 650 |
|
0 |
|a Drugs
|x Toxicology
|
| 650 |
|
0 |
|a High throughput screening (Drug development)
|
| 650 |
|
0 |
|a Toxicity testing
|
| 700 |
1 |
|
|a Jeffy, Brandon D. ,
|e editor
|
| 700 |
1 |
|
|a McDuffie, J. Eric ,
|e editor
|
| 700 |
1 |
|
|a Olaharski, Andrew J. ,
|e editor
|
| 700 |
1 |
|
|a Will, Yvonne ,
|e author
|
| 999 |
|
|
|a 1000169250
|b Book
|c OPEN SHELF (30 DAYS)
|e Tembila Campus
|